Gates Institute receives $300,000 grant for CAR T-cell manufacturing platform.

ScaleReady, Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady have collaborated to award a $300,000 G-Rex Grant to the Translational Sciences Laboratory at Gates Institute. The grant will fund the development of a modular G-Rex centric CAR T-cell manufacturing platform for cell and gene therapy programs. The platform aims to optimize space, capital, and personnel while maintaining cell health and quality. The collaboration aims to advance cell and gene therapy manufacturing.

The Translational Sciences Laboratory at the Gates Institute, a leading contract development and manufacturing organization (CDMO) based at the University of Colorado Anschutz Medical Campus, has been awarded a $300,000 G-Rex® Grant by ScaleReady. The grant will support the development of a modular G-Rex centric CAR T-cell manufacturing platform, aiming to optimize space, capital, and personnel while maintaining cell health and quality [1].

The G-Rex Grant Program, initiated by ScaleReady, has authorized over $40M in products to grant recipients, with individual awards up to $300,000. The program aims to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing. The Gates Institute will utilize the grant to optimize key CAR-T cell manufacturing steps through a structured Design of Experiments (DoE) approach [2].

As part of the grant, the Gates Institute will receive early access to CellReady's G-CAR-T™, a standardized CAR-T drug product manufacturing operation. This access emphasizes high-throughput, low-cost manufacturing, addressing fundamental cost challenges that have limited broader adoption of cell therapies [1].

The collaboration between ScaleReady, Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady underscores a strategic effort to establish the G-Rex platform as an industry standard in cell therapy manufacturing. This initiative aligns with broader industry efforts to reduce manufacturing complexity, improve scalability, and lower production costs for advanced therapies [2].

Additionally, ScaleReady has introduced a new free program called LEAN Cell & Gene™, launched in partnership with Hanson Wade, aimed at improving efficiency in CGT manufacturing. The program focuses on systematically identifying and eliminating waste, stabilizing business operations, increasing drug product quality and supply, and developing a LEAN approach to cell and gene therapy development and manufacturing [2].

The Gates Institute's receipt of the G-Rex Grant represents a significant advancement in CAR-T manufacturing platforms, positioning the organization to contribute to the broader field of cell and gene therapies. The collaboration highlights the growing importance of modular and scalable manufacturing solutions in the rapidly evolving landscape of cell and gene therapy tools [2].

References:
[1] https://www.prnewswire.com/news-releases/scaleready-announces-award-of-a-g-rex-grant-to-the-gates-institutes-translational-sciences-laboratory-302529441.html
[2] https://www.stocktitan.net/news/TECH/scale-ready-announces-award-of-a-g-rex-grant-to-the-gates-institute-o6hlo7xjb63k.html